Rapport Therapeutics, Inc.

US$24.44As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RAPPHealthcare
Country USA
PE (Fwd) •••
TSR 2Y CAGR 2.12%
Div yield —
ROE (33.33%)
Biotechnology
Beta (5Y) 1.40
PE TTM —
TSR TTM (15.52%)
Mkt cap US$1.449B
ROIC (22.67%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$32
29.84%
(19.18%)
Hold 6|6|2|10|1
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.30
0.29
0.30
0.32
5.22%
(3.14%)
2.86%
8.92%
Revenue$M
148.8
156.6
158.7
158.8
10.39%
16.23%
14.90%
8.73%
Peers (US$1.449B)
Cap (US$)
PE
1.451B
—
Capital
TTM
5Y
10Y
Leveragex
0.765
0.454
0.415
EBIT/Intx
6.777
0.397
0.385
Own earn%
23.59
(34.13)
(35.04)
Sh yield%
20.31
48.73
48.19
Owners
Insiders/Inst%
2.60
26.50
Short interest%
5.51
SBC / revenue%
5.47
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
15–19
$1 testx
—
Incr. ROIC%
1